Research on lung cancer detection and treatment. Covers microbial predictors of immunotherapy, MRI detection, microplastics, and RAS-mutant drugs.
Researchers identified a new biomarker, TTF-1, that predicts survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib. Patients with low TTF-1 levels responded poorly to sotorasib, while those with high TTF-1 levels showed improved outcomes.
The University of Houston has launched a $3M Cancer Immunotherapy Biomarker Core to accelerate early diagnosis and treatment response in cancer. The core will offer comprehensive targeted proteomic cancer biomarker screens, enabling researchers to identify better biomarkers for cancer.
The study evaluated the mutation profiles of lung squamous cell carcinoma (LSCC) detected by next-generation sequencing to assess relationships with clinicopathological parameters. Detection of mutations revealed associations between certain genes, such as PIK3CA and NF1, with specific histopathological features.
Four Weill Cornell Medicine investigators received the Ritu Banga Healthcare Disparities Research Awards to tackle disparities in cancer care, racial and ethnic differences in pediatric Hodgkin lymphoma, and access barriers to high-quality surgical cancer care. The awards support innovative research aimed at improving health outcomes f...
Researchers will present AI models that predict chronic respiratory failure and detect airway obstruction, with key findings on asthma susceptibility, small airway disease, and lung inflammation. The studies use nasal epithelial gene expression analyses and bronchoscopy to identify potential biomarkers for ICU patient outcomes.
A deep learning model called Sybil can predict future lung cancer risk from a single low-dose chest CT scan. The model demonstrated good performance in predicting cancer diagnosis at both one and six years, including in never-smokers.
A nationwide cohort study found that immune checkpoint inhibitors significantly increase the risk of myocarditis in NSCLC patients, with a 7.4-fold increase in risk compared to non-users. Cardiac monitoring for at least six months following ICI initiation is recommended.
Researchers investigated pleurodesis treatment for lung cancer patients with interstitial lung disease, finding an efficacy rate of about 70% with talc and minocycline. However, cases with partially expanded lungs or recent systemic prednisolone treatment increased the risk of acute respiratory distress syndrome.
Researchers found that using current lung cancer screening criteria may overlook at-risk populations, such as older adults and non-English speakers. Incorporating additional factors could enhance diagnostic screening effectiveness in Emergency Department patients.
The study demonstrated the diagnostic utility of endobronchial ultrasound elastography for detecting benign and malignant lymph nodes. The combined index of elastography grading score and short diameter yielded an area under the receiver operating characteristic curve of 0.702, indicating moderate accuracy.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
Two new predictive algorithms use health data and blood tests to identify high-risk patients, offering improved accuracy in diagnosing cancers. The models identified additional medical conditions associated with increased cancer risk and new symptoms indicative of multiple cancer types.
This study compares laser-guided technology to conventional manual percutaneous lung biopsy, finding that laser-guided technology can reduce operational time and needle adjustments. However, it did not reduce complication rates or improve pathological diagnosis accuracy compared to traditional methods.
The APPLE trial updated investigated the treatment strategy's impact on brain metastasis control and circulating tumour DNA progression-free survival. The study found no significant differences between upfront osimertinib or sequential treatment, but suggested a viable option for regions with first-line osimertinib access issues.
A new study found that neoadjuvant dual immuno-combination therapy with relatlimab and nivolumab achieved a 93% one-year disease-free survival rate and 100% one-year overall survival rate in patients with resectable non-small cell lung cancer. The therapy also showed promising outcomes, including a pathological complete response rate o...
A new study introduces the RAPID-RT study, which uses a rapid-learning approach to evaluate the impact of treatment modifications in radiotherapy. The technique aims to reduce cardiac toxicity and improve survival in lung cancer patients by minimising dose to the top of the heart, a previously identified risk area.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Researchers have developed three-dimensional spheroid cultures that better replicate cell-cell interactions and nutrient gradients, leading to a greater understanding of tumour tissue behaviour and drug responses. The study highlights the importance of mimicking tumour architecture in testing cancer therapies.
A non-risk-based lung cancer screening approach using low-dose computed tomography (LDCT) in Chinese populations detects a significant number of early-stage lung cancers. The study found that incorporating non-high-risk individuals into screening programs can lead to a greater detection rate and improved patient outcomes.
A new study found that pregnancy-related glycoproteins (PSGs) are strongly associated with poorer outcomes in female lung cancer patients. The analysis suggests targeting these genes may improve survival in female patients with lung cancer, and the researchers plan to pursue further investigation into their role.
A Phase Ia/Ib trial found that zongertinib demonstrated clinical benefits for patients with advanced HER2-mutant non-small cell lung cancer, particularly those with specific HER2 mutations. The treatment showed a 71% objective response rate and manageable side effects.
The phase Ia/Ib Beamion LUNG-1 trial found that zongertinib elicited durable responses in patients with advanced, previously treated non-small cell lung cancer (NSCLC) harboring a HER2 mutation. The disease control rate was high across cohorts, with median progression-free survival ranging from 12.4 to 6.8 months.
A phase I clinical trial found that zoldonrasib elicited objective responses and disease control in patients with KRAS G12D-mutated NSCLC. The study demonstrated the efficacy and tolerability of the oral agent, which selectively targets the active conformation of KRAS.
A recent study found that cigarette smoking continues to decline across the US, mainly driven by young adults. The states with historically high smoking rates have seen the most significant declines in smoking prevalence.
Researchers found that blood cells carrying age-related mutations can infiltrate tumours, leading to worse cancer outcomes. The presence of these mutations was associated with shorter survival rates in patients with lung and other aggressive cancers.
A recent preclinical study from Weill Cornell Medicine researchers suggests that three-dimensional gene hubs may promote brain cancer. The findings, published in Molecular Cell, offer a new way to think about cancer beyond gene mutations and highlight the importance of understanding DNA organization in tumor cells.
Researchers developed an AI algorithm based on the medical history of over half a million patients, enabling GPs to identify increased risk of lung cancer up to 4 months before diagnosis. This method may also offer early detection for other types of cancer and improved patient outcomes.
Liquid biopsy analyzes circulating tumor components in body fluids to detect cancer at early stages, offering a safer and more dynamic alternative to traditional tissue biopsies. This non-invasive approach has shown promise in detecting various types of cancer, including lung, breast, colorectal, prostate, and gastric cancers.
The Lung-MAP 3.0 trial introduces a simplified genomic screening process, allowing most patients to be matched to a targeted treatment sub-study based on prior testing results. This expansion increases access to investigational treatments for patients with advanced non-small cell lung cancer.
A new study published in The Annals of Thoracic Surgery found that Medicaid expansion significantly improved access to timely treatment for patients with early-stage non-small cell lung cancer. High-volume hospitals associated with decreased postoperative complications and in-hospital mortality rates compared to low-volume hospitals.
A new study suggests that CT scans could account for 5% of all cancer cases each year, primarily due to radiation exposure. The largest risk is among infants, followed by children and adolescents. To mitigate this risk, reducing the number of scans and doses per scan can help save lives.
A study by the University of Barcelona reveals that dynamic BH3 profiling can predict the effectiveness of ALK inhibitors in treating non-small cell lung cancer. The technique helps select the best drug for each patient, overcoming tumour adaptations to inhibitors.
Researchers at KAIST discovered that DDX54 is the master regulator hindering immunotherapy's effectiveness in lung cancer. Supressing DDX54 enhances immune cell infiltration into tumors and improves immunotherapy efficacy.
The American College of Chest Physicians' CHEST Critical Care and CHEST Pulmonary journals have been indexed in Elsevier's Scopus database. This achievement is a testament to the high-quality research published in these journals, which provide open access content in pulmonary and critical care medicine.
A new study by Mass General Brigham researchers reveals that many eligible patients who receive other preventative screenings are not getting screened for lung cancer. The study found that 65% of those eligible received breast and colorectal cancer screening, a nearly 4-fold higher rate than lung cancer screening.
Researchers found significant cell changes in workers exposed to hexavalent chromium at levels below Sweden's current limit. The study suggests the need for stricter safety regulations and lower limits for this carcinogenic substance.
Researchers discovered TBX2 drives therapy resistance by shifting signaling from the androgen receptor to the glucocorticoid receptor. The study identified a strategy to target this switch, potentially predicting patient risk and offering new treatment approaches.
Researchers at MD Anderson Cancer Center made several key discoveries, including the spatial organization of cancer-associated fibroblasts across various cancers and a study on treatment resistance in SMARCA4-mutant lung cancer. These findings highlight the importance of investigating cell populations in their spatial context to better...
A new study published by the American Cancer Society estimates that tobacco control measures have averted over 3.8 million lung cancer deaths and gained 76 million years of life in the US between 1970 and 2022. The study highlights the significant impact of progress against smoking on reducing premature mortality from lung cancer.
A study published in the British Journal of General Practice found a significant link between chest x-ray referrals and earlier lung cancer diagnosis and better survival rates. Patients attending practices with high chest x-ray usage were more likely to be diagnosed at an earlier stage, leading to improved survival rates.
Dr. John Turchi, a leading lung cancer researcher, has been appointed as the inaugural executive director of the Tom and Julie Wood Center for Lung Cancer Research at Indiana University. The center aims to advance lung cancer research and improve patient outcomes through innovative therapies and personalized care.
New leukemia treatment combination shows promise for patients with follicular lymphoma. Immunotherapy research also explores ways to suppress protein ZNF638 to boost effectiveness of immune checkpoint inhibitors. Innovative funding efforts support Sylvester's cancer research initiatives.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
The European Lung Cancer Congress 2025 will take place in Paris from March 26-29, featuring renowned experts discussing the latest research on lung cancer prevention, diagnosis, and treatment. The congress will also include award lectures and live streaming of the event.
The updated guidelines substantially increased lung cancer screenings overall, but disparities persist among people with limited access to healthcare. Barriers include cost, knowledge, and lack of primary care providers, with mobile units and patient navigators offering potential solutions.
A multicenter cohort study found that higher adherence to annual lung cancer screening was associated with increased overall and early-stage lung cancer detection rates. However, adherence decreased over time, suggesting it is a critical quality metric for lung cancer screening.
This cohort study found that geographic access to cancer care is associated with guideline-recommended treatment for early-stage non–small cell lung cancer. Socially marginalized patients benefited from improved treatment outcomes and prognosis when accessing care in their local area.
A post-treatment blood test measures cancer-derived molecules in patients with lung cancer years after treatment. This tool can inform clinical intervention, including restarting or intensifying treatment for high-risk patients.
Researchers found that a Western-style diet high in glycogen can fuel lung cancer tumors, leading to faster growth and worse outcomes. A nutrient-rich diet, active lifestyle, and reduced alcohol intake are recommended for lung cancer prevention.
Breast cancer death rates are predicted to increase in EU patients aged 80 years and older, while falling in all other age groups. This is attributed to a lack of regular screening and access to modern treatments.
Scientists at VCU Massey Comprehensive Cancer Center have discovered a powerful combination therapy that leverages sotorasib and FGTI-2734 to tackle drug resistance in lung cancer. The treatment targets the KRAS G12C mutation, which is responsible for about 14% of non-small cell lung cancers.
A study of nearly 2,500 postmenopausal women found that taking more daily steps and engaging in moderate-to-vigorous physical activity were associated with a significantly reduced risk of death from cardiovascular disease. Even walking fewer than 5,000 steps per day showed a risk reduction.
Short-course corticosteroid treatment was associated with lower surgical site complications and in-hospital mortality in patients with postoperative acute lung injury following lung resection surgery. The optimal duration of corticosteroid treatment remains uncertain, highlighting the need to weigh benefits against adverse effects.
Researchers at Tufts University have developed a cancer vaccine that amplifies the visibility of tumor antigens to the immune system, leading to potent responses and lasting immunological memory. The vaccine works against multiple solid tumors in animal models, including melanoma, triple-negative breast cancer, and ovarian cancer.
The hybrid operating room enables the entire procedure to be performed in a single step, allowing for more precise positioning of the thoracic endoprosthesis. This approach requires collaboration between thoracic surgeons and vascular surgeons.
Cancer cells work together to source nutrients from their environment, a cooperative process that can be targeted for treating cancer. Researchers identified key enzymes and mechanisms behind this cooperation, including the enzyme CNDP2, which can be inhibited by the drug bestatin.
A new laser-based device can analyze gas samples with high precision, detecting molecules at minute concentrations. The technology has potential applications in medical diagnostics, tracking greenhouse gas emissions, and more.
The Lung Cancer Research Foundation and Israel Cancer Research Fund are partnering to test an innovative new treatment for lung cancer. The project aims to explore the effects of a drug that targets IGF2BP1, a protein involved in cancer cell growth.
A study found that 77.9% of lung cancer patients had detectable atherosclerosis on CT scans, with smoking being the most prominent cardiac risk factor. The results suggest using concurrent coronary calcium scoring to aid in identification and earlier intervention for these patients.
A study found that MAGE-4 drives the accumulation of plasma immune cells suppressing antitumor immunity in mouse and human non-small cell lung cancer models. The protein promotes tumor progression by losing a tumor suppressor gene, PTEN, accelerating development into metastasis.